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When Enough Is Enough*Nir Ayalon, MD, Alice K. Jacobs, MDSEE PAGE 207T he optimal degree of revascularization forpatients with multivessel coronary arterydisease is not well established. Although
there is growing evidence to support early and more
complete revascularization of signiﬁcant noninfarct
artery stenoses among selected patients with ST-
segment elevation myocardial infarction (STEMI)
(1,2), there are few prospective studies evaluating
patients with acute coronary syndromes or stable cor-
onary disease to support a similar approach (3,4).
Therefore, the decision whether to pursue multives-
sel or more limited percutaneous coronary interven-
tion (PCI) continues to remain discretionary, and
dependent on multiple factors including the patient’s
clinical status, severity and distribution of the coro-
nary artery disease, characteristics of the stenoses,
degree and location of ischemic and/or viable
myocardium, left ventricular function, and other
comorbidities.
However, the advantage of a strategy of complete
revascularization to decrease subsequent cardiovas-
cular events seems intuitive. This concept was sup-
ported by early studies in patients undergoing
coronary artery bypass graft (CABG) surgery where
the beneﬁt of complete revascularization was
demonstrated (5). Furthermore, subsequent ran-
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associated with improved outcomes (particularly in
patients with diabetes and with complex coronary
anatomy) (6,7), mostly due to less repeat revascular-
ization (6,8,9). Yet, since its introduction into clinical
practice, single vessel (“culprit lesion”) PCI has been
performed in the majority of patients with multi-
vessel disease, fueled by the concept of correct
identiﬁcation of the “culprit lesion” and by favorable
outcomes associated with this approach (10). Indeed,
in the 1977 to 1981 initial National Heart, Lung and
Blood Institute (NHLBI) Percutaneous Transluminal
Coronary Angioplasty (PTCA) registry, 25% of patients
had multivessel disease, and 14% of procedures
involved attempts to dilate lesions in more than 1
vessel (11). In more contemporary experience, nearly
72% of patients undergoing PCI within the National
Cardiovascular Data Registry in 2010 to 2011 had
multivessel disease although 86% underwent single-
vessel PCI (12). Moreover, in the SYNTAX (SYNergy
between PCI with TAXus and Cardiac Surgery) trial
comparing PCI and CABG for triple-vessel or left main
disease, complete revascularization was performed in
only 56.7% of patients in the PCI group (9).In this issue of JACC: Cardiovascular Interventions,
Hambraeus et al. (13) describe the practice of
incomplete revascularization and its association with
a pre-deﬁned composite endpoint of all-cause death,
myocardial infarction, and repeat revascularization at
1 year. Patients with multivessel coronary disease
treated with PCI between 2006 and 2010 within an
observational study of prospectively collected data
from SCAAR (Swedish Coronary Angiography and
Angioplasty Registry) merged with ofﬁcial Swedish
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217health data registries were evaluated. Of 23,342 pa-
tients, 15,165 (65%) were classiﬁed as incomplete
revascularization at the end of the index procedure.
Incomplete revascularization was deﬁned as any
untreated signiﬁcant stenosis (more than 60% of
the vessel diameter) in a coronary artery supplying
more than 10% of the myocardium. Incomplete
revascularization patients were older with more
comorbidities and higher prevalence of female sex,
more often presented with STEMI, received more
emergency procedures during the afterhours, had
more extensive coronary disease, received fewer
stents and more drug-eluting stents, and were
more likely to be discharged with long-acting
nitroglycerin. All-cause mortality (7.1% vs. 3.8%),
myocardial infarction (10.4% vs. 6.0%), and repeat
revascularization (20.5% vs. 8.5%) were higher in
the incomplete compared with the complete revas-
cularization group. Propensity score matching (39%
of the incomplete revascularization group) revealed
a signiﬁcantly higher adjusted hazard ratio (HR)
for the composite of death, myocardial infarction,
or repeat revascularization at 1 year in the in-
complete revascularization group (HR: 2.12; 95%
conﬁdence interval [CI]: 1.98 to 2.28; p < 0.0001).
Adjusted HR for death (1.29, 95% CI: 1.12 to
1.49; p ¼ 0.0005) and death/myocardial infarction
(1.42, 95% CI: 1.30 to 1.56; p < 0.0001) was also
higher, suggesting that incomplete revascularization
at the time of hospital discharge was associated
with an increased risk of adverse outcomes within
1 year.
This study adds to growing evidence suggesting that
complete revascularization should be the preferred
strategy in patients with multivessel coronary disease
and that it is related to favorable outcomes. Not-
withstanding the absence of data that would inﬂuence
the revascularization approach including clinical
(recurrent ischemia, ongoing angina symptoms),
functional (left ventricular ejection fraction, resting
or stress echocardiography, myocardial perfusion
studies, or other imaging modalities), speciﬁc an-
atomic (presence of chronic total occlusions), and he-
modynamic (fractional ﬂow reserve) variables, or
procedural restrictions and challenges (volume of
contrast, radiation dose, operator fatigue), the present
study is fortiﬁed by experienced investigators and a
robust database that has contributed to numerous
clinical studies. Moreover, thoughtful analyses were
performed to account for baseline differences between
groups, potential staged PCI procedures, duration
of dual antiplatelet therapy, and change in revascu-
larization group following subsequent PCI. How-
ever, perhaps most important, is the absence of theintent of revascularization, that is, whether incom-
plete revascularization was intended or the result of a
procedural complication or an uncomplicated tech-
nical failure.
Observational studies comparing complete with
incomplete revascularization have been limited by
the bias to perform incomplete revascularization in
sicker, more complex patients and by the lack of a
universal and consistent deﬁnition of the terms.
Revascularization decisions are often based upon the
integration of factors not routinely collected in reg-
istries (or in those excluded from participation in
randomized trials) such as frailty, bleeding risk,
ability to comply with dual antiplatelet therapy, pa-
tient preference and quality of life. Revascularization
approaches are also based upon the potential to
achieve completeness deﬁned on an anatomic basis
as well as on a functional basis. Whereas complete
anatomic revascularization is most often deﬁned as
treatment of all stenoses greater than or equal to
either 50% or 70% of vessel diameter in vessels with
distal size >1.5 or 2.0 mm in diameter, complete
functional revascularization is deﬁned as treatment
of all anatomically signiﬁcant stenoses (or with frac-
tional ﬂow reserve #0.8) serving ischemic, viable, or
noninfarcted myocardium. This supports the concept
of incomplete anatomic, but complete functional,
revascularization that is both adequate and may be
intended. It follows that incomplete revascularization
that is unintended would occur when all lesions
serving viable myocardium are not adequately
treated.
Prior smaller studies and subset analyses have
shown that planned or intended incomplete revas-
cularization in patients with multivessel coronary
disease is unrelated to risk of cardiac death or death/
myocardial infarction, but independently associated
with subsequent CABG at 5 years (10,14). Moving
forward, it will be helpful to adequately evaluate a
strategy of intended, incomplete, but functionally
adequate PCI, particularly in patients deemed to be at
high risk for complete revascularization (that may be
unnecessary). Careful consideration of the spectrum
of incomplete revascularization employing catheter-
based tools to measure fractional ﬂow reserve and
assess physiological and functional signiﬁcance of
coronary stenoses and newer imaging modalities to
evaluate ischemia and viability may improve out-
comes for patients across the continuum of stable
ischemic heart disease, acute coronary syndromes,
and STEMI.
When advances in technology essentially eliminate
stent thrombosis and decrease in-stent restenosis
to a few percent, or allow us to identify and
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218prophylactically treat vulnerable plaque so as to
preserve myocardium against future events (similar
to CABG), complete revascularization may become
the norm. Until then, the ideal degree of revascular-
ization in patients with multivessel disease may
remain unclear. Although the totality of data suggests
that complete, in comparison to generally deﬁned
incomplete, revascularization is associated with more
favorable outcomes, yet to be determined is whether
performing complete revascularization will improve
outcomes in the presumably more complex, incom-
plete revascularization patient group in whom
jeopardized myocardium remains. Absent robustevidence to inform our clinical practice guidelines and
management decisions, it is the individual physician
and patient who will continue to synthesize the clin-
ical, angiographic, and procedural variables supported
by anatomic, hemodynamic, and functional studies in
addition to quality-of-life preferences and to deter-
mine together, how much revascularization is enough
revascularization.
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